drugset / Trial / NCT04602221

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

NCT04602221

Phase 1 Completed 40 enrolled Boehringer Ingelheim
RandomizedCrossoverTriple-blindTreatment

Summary

The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.

Timeline

Start
2020-12-01
Primary completion
2022-08-01
Completion
2022-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Iclepertin Small molecule
Subject Lamotrigine Small molecule
Subject OSORESNONTRINE Small molecule

Indications

No indication recorded.